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1. PERSPECTIVE ON REGIONAL CANCER 
CHEMOTHERAPY 
A number of common tumors have a propensity for confinement to specific body regions 
or organs. In a significant number of patients it is the regional tumor, and not widespread 
metastases, which causes morbidity and eventually death. In a few circumstances, surgical 
resection of isolated metastases can be curative. For example, resection of a single, isolated 
hepatic nodule can lead to a cure in up to 25~ of cases (Latham and Foster, 1967). 
Unfortunately, even regionally confined metastases are seldom single and are often 
surgically unresectable due to anatomical location. When all metastatic tumors can be 
encompassed in a radiation port with sufficient sparing of vital tissues, high dose 
radiotherapy can sterilize such disease. However, normal tissue tolerance to radiotherapy 
often impedes the delivery of curative dosages. Regional chemotherapy represents a third 
potent approach useful in regionally confined cancers. 
Even in circumstances where systemically administered (intravenous) chemotherapy is 
relatively ineffective, regional chemotherapy may still improve the likelihood of response 
by the generation of much greater drug exposures (higher levels, longer times). Regional 
chemotherapy administration represents a means to generate increased drug exposure in 
the region where the tumor resides while maintaining a lower drug exposure at the level 
of dose-limiting normal host tissues elsewhere in the body. Ideally, the higher level of drug 
generated regionally will be cytotoxic to the regionally confined tumor while the lower 
systemic drug level will be below the toxic threshold for the usual dose-limiting tissues such 
as the bone marrow and gastrointestinal mucosa. With sufficient regional selectivity, 
dose-limiting toxicity should be manifested by the normal tissues of the region infused and 
not by tissues elsewhere in the body. In this regard, regional chemotherapy has similarities 
to radiation therapy but may be more selective when tumor and normal tissue in the 
treated region differ greatly in intrinsic drug sensitivity (based upon biochemical 
differences). 
As will be described below, regional drug exposures may be increased 100- to 1000-fold 
per given amount of systemic exposure. Such selective improvements are due to the 
pharmacokinetics of individual agents and to restricted egress from regional compartments 
or to circumscribed, relatively low regional blood flows. Despite improved regional drug 
exposure, antineoplastic effect may not be improved if a tumor is either too sensitive or 
too refractory. If a tumor is extremely sensitive to a given drug, systemic administration 
may suffice to achieve maximum therapeutic effect. If a tumor is totally refractory to all 
concentrations of a drug, then the increased exposure generated through regional 
chemotherapy will be of no benefit. 
Regional chemotherapy can be divided into two major categories: administration into 
a third space regional compartment (cerebrospinal fluid (CSF) space, peritoneal cavity, 
pleural space, pericardial space) and, intraarterial infusion into the afferent artery feeding 
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the tumor-containing organ or body region. The principles involved are broadly applicable 
within each category and, therefore, only the most frequent and significant regional 
chemotherapies will be discussed below. 
Interest in regional chemotherapy has been stimulated by two recent developments in 
clinical pharmacology. The first is the ability to measure drug levels readily in body fluids. 
Although a number of  techniques have been utilized, high performance liquid chro- 
matographic assays have been developed for most  antineoplastic agents of  interest. Hence, 
the basic pharmacokinetic properties relevant to a drug's potential usefulness in regional 
chemotherapy often are determined early in clinical protocols. When a given drug has the 
appropriate properties, the improved regionally selective drug levels can be directly 
measured in clinical practice. The dependence of  selectivity on route of  administration, 
dose rate, schedule, infusion volumes, etc. can be ascertained comparing regional drug 
levels with systemic drug levels (Ensminger et al., 1978a). 
The second impetus to regional chemotherapy has been the development of  improved 
devices for the controlled delivery of drug solutions into appropriate blood vessels or body 
spaces. Extracorporeal volumetric infusion pumps have improved accuracy and reliability. 
With refinement in drug therapy and more potent drugs, such external infusion pumps 
have proliferated in numbers within the hospital setting. Portable external pumps have 
come into use and are being refined. However, the development of  a totally implanted 
pump (Blackshear et al., 1970; Buchwald et al., 1980; Ensminger et al., 1981a) has made 
it possible to give protracted infusions safely and reliably to outpatients with relatively few 
restrictions on the patient 's lifestyle. The only commercially available pump, the Model 
400 Infusaid Pump (Fig. 1) has been implanted in over 2,000 patients (B. Enegren, Sales 
Manager,  Infusaid Corp., Sharon, Ma., personal communication). Although the majority 
FIG. 1. Diagram of the Model 400 Infusaid pump produced by Infusaid Corporation, Sharon, MA. 
The Model 400 pump has a side port with an auxiliary septum which bypass the pumping 
mechanism for direct catheter injection. The disc-shaped pump is separated into two chambers by 
titanium bellows. The inner drug chamber contains the solution to be infused. The outer chamber 
contains a fluorocarbon liquid in equilibrium with its vapor phase. At 37°C, the vapor pressure 
exerted by this substance is approximately 300mmHg greater than atmospheric pressure. This 
vapor pressure provides the power source, exerting pressure on the bellows and forcing infusate 
through a 0.22 #m bacterial filter and a flow-regulating resistance element. The pump is placed 
beneath the skin, and the inner drug chamber is refilled by percutaneous injection though a 
self-sealing septum. The pressure of this injection compresses the fluorocarbon vapor back to the 
liquid phase, thus simultaneously filling the pump and recharging the power source. The pump has 
a 50 ml capacity and flow rates of individual pumps are factory calibrated to deliver a constant 
set rate, usually, in the range of 2-3 ml/day. Diagram courtesy of Infusaid Corporation. The 
UNFUSAID TM pump is the only commercially available implantable pump and has been 
implanted in over 2000 patients. 
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of pumps being impanted are for hepatic arterial chemotherapy, some are being used for 
intrathecai morphine infusions for pain control (Greenberg et  al., 1982), for intra- 
ventricular and intraarterial treatment of central nervous system tumors (Dakhil et al., 
1981a; Phillips et al., 1982), for intravenous infusions of heparin in thrombotic disorders 
(Rohde et al., 1977), and for intravenous infusions of insulin in Type II diabetes (Buchwald 
et  al., 1981). Externally programmable, yet totally implantable, infusion pumps produced 
by a number of manufacturers are in early clinical trails (Schade et al., 1982). Implantable 
pumps are not suitable for drugs requiring administration in large fluid volumes, for drugs 
that are unstable, and for drugs best administered in boluses or short infusions. However, 
even for such drugs and in circumstances where reliable repeated access is required, small 
implanted injection ports attached to silastic catheters can provide a safe and convenient 
means of access (Gyves et  al., 1982a). 
2. THIRD SPACE CHEMOTHERAPY 
There are a number of circumstances where tumors are largely confined to body cavities 
(or third spaces) without significant invasion into lining tissues. Examples are meningeal 
carcinomatosis in the cerebrospinal fluid (CSF) space and malignant ascites within the 
peritoneal cavity. Direct drug instillation into the CSF space has been frequently practiced 
for control of meningeal tumor using methotrexate (MTX) most commonly (Shapiro et 
al., 1975; Bleyer and Poplack, 1978). In the past few years, direct drug administration into 
the peritoneal cavity has also been extensively investigated (Dedrick et al., 1978; Speyer 
et al., 1980). The pharmacological principles applicable to these two spaces have 
similarities and can be generalized to other body spaces such as the pleural and pericardial 
cavities (Howell et  al., 1981). 
2.1. THIRD SPACE PHARMACOKINETIC PRINCIPLES 
The pharmacokinetic properties of a given drug determine whether direct administration 
into a given body space will be advantageous in terms of generating increased drug 
exposure in the fluid (and on the surfaces lining that space) relative to systemic exposure. 
The pharmacokinetic modeling appropriate to antineoplastic drugs for third space 
administration has been defined (Dedrick et al., 1978; Howell et  al., 1981). A drug within 
the body cavity crosses the lining membrane of area (A) by a diffusive process character- 
ized by a permeability (P). As commonly practiced, the intrinsic P is not measured 
separately, but only in combination with the associated A to generate a permeability-area 
product ( P A  ). 
2.2.1. C S F  Space  
Using a simplified two compartment model (Bleyer and Dedrick, 1977), the mass balance 
equation is 
dCcsv 
-- VCNS d t  -- r + P A  (Ccsv -- Cp) + QcsF" CCSF (1) 
where Vcss equals the volume of CSF plus the extracellular fluid volume of the brain and 
spinal cord, CcsF the CSF drug concentration and Cp the plasma drug concentration, QcsF 
the rate of bulk flow of CSF from the CSF space by arachnoid villi uptake and, r the active 
transport component (r is felt to be 0 for MTX). For MTX, P A  is approximately 1 ml/hr 
with a CSF bulk flow (QcsF) of approximately 30 ml/hr or 0.5 ml/min (Bleyer and Dedrick, 
1977). Hence, bulk flow dominates removal of MTX from the CSF space. Since MTX is 
not metabolized in the CSF space, steady state infusion into the CSF space at rate I leads 
to steady-state infusion into the vascular compartment (or systemic circulation) at rate I. 
The resultant systemic plasma level (Cp) is related to the infusion rate and total body 
clearance (CLTB) as follows: 
Cp = I /CLTB (2) 
JPT  21 /2- - J  
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If the steady state dose rate of MTX infusion into CSF space is much larger than the 
quantity of drug transported from plasma back to CSF space, then 
and, 
CcsF ~ I/Qcsv (3) 
Ccsv/Cp -~ CLTB/QcsF (4) 
For MTX which is excreted primarily by the kidneys, C/-,rB equals or exceeds creatinine 
clearance and thus is usually at least 100 ml/min. Hence, with direct CSF space infusion 
of MTX, 
100 ml/min 
Selective advantage = CCsF/C p "~ 0.5 ml/min ~ 200 (5) 
A totally implanted system for direct constant intraventricular infusions has been 
developed in monkeys and utilized in patients with central nervous system (CNS) tumors 
(Dakhil et al., 198 l a). Using this system in patients, the selective advantage at steady-state 
for direct intraventricular infusion of MTX exceeds 200, which is as predicted above. 
Assuming that the bulk flow rate, QCSF, is relatively constant at approximately 0.5 ml/min, 
then CLrB becomes the crucial factor in determining the selective regional advantage of 
any given drug. It will be seen later that a drug's total body clearance is a crucial selective 
factor also with infusions into other body cavities as well as with regional intraarterial 
infusions. 
Fluorodeoxyuridine (FUDR) and cytosine arabinoside (AraC) are two pyrimidine 
antimetabolites which have even higher CLrB than MTX. Constant intraventricular 
infusion of FUDR, in particular, generates at least a 1000-fold higher steady-state CSF 
space level than plasma level (Dakhil et al., 1981b). The P A ' s  for FUDR and AraC have 
not been determined, but are probably greater than that for MTX based on their CSF 
pharmacokinetics in comparison with ytterbium-169 labeled diethyltriamine pentacetic 
acid (DTPA), an agent which is removed from the CSF space solely by bulk flow. 
Although a system for constant CSF space drug infusion has been recently developed, 
the vast majority of prior investigational and clinical usages have concerned bolus drug 
injections into the CSF space (Bleyer and Poplack, 1978). The development of ventricu- 
lostomy reservoirs has greatly facilitated repeated access to the entire CSF space. Injection 
of a drug solution into a lateral ventricle leads to distribution throughout the CSF space 
as most CSF is produced by the ventricular choroid plexus, whereas, injection of drug into 
the lumbar sac does not always lead to adequate retrograde drug flow into the ventricles 
(Rieselbach et aL, 1962; Shapiro et al., 1975). With bolus intraventricular injection of 
MTX, CSF drug levels are generated which are several hundred-fold concurrent systemic 
levels (Shapiro et al., 1975). MTX levels are not uniform throughout the CSF space at any 
given time-point due to bulk flow of CSF from the site of injection with continued CSF 
production. Systemic plasma levels rise and peak over 4-8 hr with the arrival of the wave 
of MTX-containing CSF at the arachnoid villi. Both CSF and plasma levels fall in a 
relatively parallel fashion with time thereafter. The systemic plasma levels achieved with 
bolus intraventricular injection may exceed the toxic threshold for a long enough time to 
generate systemic toxicity with MTX. Frequent intraventricular injection of much smaller 
MTX doses has been proposed as a mechanism to sustain therapeutic CSF space drug 
levels without the generation of toxic systemic levels (Bleyer et al., 1978). As depicted in 
Fig. 2, constant intraventricular infusion offers the best method for precise maintenance 
of a high CSF level with a lower systemic level. Other factors such as cost and risks of 
an implanted system as well as duration of need for therapy will play an important role 
in determining whether to implant a pump for constant infusion or to simulate a constant 
infusion with multiple daily injections. With antimetabolites such as MTX, AraC and 
FUDR, cytotoxicity is related to duration of exposure above a threshold concentration 
with the toxic threshold and duration variable from tissue to tissue (Pinedo and Chabner, 
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FIG. 2. Simplified graphic representation of resultant CSF and plasma drug levels after twice daily 
intraventricular bolus versus constant intraventricular infusion of a chemotherapeutic agent such 
as methotrexate. A controlled constant infusion at the correct level should not generate toxic peak 
levels or less than therapeutically optimal trough levels. 
1977). These antimetabolities are cell-cycle and phase-specific which means that non- 
proliferating cells such as normal brain and stromal tissues are less sensitive than 
proliferating tumor cells. The longer the drug exposure is maintained above the toxic 
threshold for the tumor cells in the CSF space, the greater the proportion of  tumor cells 
which will be destroyed. 
The only other antineoplastic agent used intrathecally has been the alkylating agent, 
thio-tepa (Gutin et al., 1976). Thio-tepa is more lipid soluble than the aformentioned 
antimetabolies and therefore is likely to be more readily absorbed (i.e. have a larger PA) 
from the CSF space than MTX, AraC and FUDR.  It is noteworthy that alkylating agents 
affect cytotoxicity more in relation to their peak level than duration of exposure. Hence, 
bolus administration of  intraventricular thio-tepa would seem to be the most rational 
schedule. 
2.1.2. lntraperitoneal and other Third Spaces 
The pharmacokinetic rationale for the intraperitoneal administration of  antineoplastic 
agents has been delineated by Dedrick and associates at the National Cancer Institute 
(Dedrick et al., 1978) and generalized to pleural and pericardial administration of MTX 
by Howell and associates (Howell et al., 1981). At steady state, the selective advantage of  
a direct drug infusion into a third space in terms of  third space level (CTs) to systemic 
plasma level (Cp) relates as follows to the total body drug clearance (CLrB) and the 
permeability-area product (PA) 
CTs R ( P A ) + C LTB 
Selective a d v a n t a g e -  - (6) 
Cp PA 
where R represents the effusion to plasma MTX concentration partition ratio determined 
by equilibrium dialysis (required to account for plasma protein binding). When R equals 
1 as it is for MTX, then: 
Selective advantage = CTs (CLra ' ]  
C-~= I + \ P A ]  (7) 
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TABLE I. Selectivity o f  Direct Drug Infusions Into Third Spaces 
Concurrent Drug Levels (/~M) 
Space Drug Third Space (Crs) Plasma (Cp) CTs/Cp Reference 
CSF MTX 2-30 <0.01 200-300 Dakhil et al., 1981a 
CSF FUDR 4-14 <0.01 200-14,000 Dakhil et al., 1981b 
Peritoneal FU 100-200 0.10-0.46 200-2,000 Gyves et al., 1982e 
Peritoneal MTX 24 0.7 30 Howell et al., 1981 
Pleural MTX 213 1.0 200 Howell et al., 1981 
Pericardial MTX 434 1.2 300 Howell et al., 1981 
Table 1 summarizes the data obtained by several investigators pertaining to intra- 
peritoneal MTX and fluorouracil (FU) infusions as well as to intrapleural and intra- 
pericardial MTX infusions. Thus it can be seen that for both MTX and FU, direct infusion 
into a third space generates at least 100-fold selective third space drug exposure and that 
this exposure is a function of CLra and the PA for the drug. If CLrB falls, the selective 
advantage may fall with constant PA.  Hence the importance of sustaining a high CLTB 
through maintainance of adequate hepatic and renal function. If the membrane area for 
diffusion decreases, then PA will fall, and, for constant CLTB, the selective advantage for 
the space defined by the membrane in question will rise. 
Intracavitary chemotherapy is limited in applicability to free-floating tumor cells and to 
tumors of small thickness on the lining of the cavity. Grossly visible tumors are likely to 
receive their blood supply from the systemic circulation with limited drug diffusion from 
the surface facing the cavity. Furthermore, there is difficulty quantitating response under 
circumstances where tumor is solely microscopic. The loss of malignant cytology in an 
effusion has been used by some to denote a response. Such a response can be meaningful 
only when there are no gross tumors and when the entire surface lining the cavity is being 
bathed by the drug-containing solution (i.e. there should be no loculated sanctuaries with 
limited access to the drug solution). 
Interest has been stimulated in the use of intraperitoneal chemotherapy for the treatment 
of ovarian cancer, particularly in an adjuvant setting (Dedrick et al., 1978). Ovarian cancer 
spreads intraabdominally within peritoneal fluid. Single cells implant on the peritoneal 
surface, exfoliate and migrate intraperitoneally via the ascitic fluid to new sites. Applica- 
tion of intraperitoneal therapy can expose individual floating tumor cells and microscopic 
surface implants to much higher drug levels than achievable with systemic infusion. Such 
high drug levels may directly kill tumor cells, but, in addition, may change the peritoneal 
surface so that implantation becomes less likely (a poor soil hypothesis). The results of 
these efforts to date are preliminary but suggest that intraperitoneal chemotherapy may 
be effective in adjuvant therapy for early stages of ovarian cancer (Ozols et al., 1982). 
About 70~ of intraperitoneal FU exists via the portal vein (Speyer et al., 1981). With 
intraperitoneal FU administration, portal vein drug levels are about 4-fold higher than 
those generated by intravenous administration of FU at the same dose rate. In addition, 
it is likely that the lymphatic drainage from the peritoneal cavity contains high drug 
concentrations with intraperitoneal FU administration. As further discussed below, 
increased intraperitoneal drug exposure and portal vein FU levels with intraperitoneal FU 
administration may be advantageous in the adjuvant treatment of high risk colon cancer. 
For hepatic tumors it is likely that the original microscopic (metastatic) tumor cell 
deposits derive much of their blood supply from the portal vein (Ackerman et al., 1969). 
Hence, for adjuvant treatment of microscopic liver metastases, portal vein infusions or 
intraperitoneal drug infusions may be rational. However, with the neovascularization 
accompanying tumor growth, the portal supply is obliterated and the arterial supply 
becomes predominant for grossly detectable disease (Breedis and Young, 1954). 
Without adjuvant treatment, primary resection of colon cancer which has penetrated 
through the bowel wall to the serosa and adjacent lymph nodes (Dukes C) leads to cure 
in only 25~ of patients. In one British study, constant infusion of 1 g/day of FU into the 
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portal vein for seven days post-operatively after primary resection of Dukes C lesions led 
to a reduction in relapse rate at two years from 68 to 17~ (Taylor et al., 1979). Direct 
intraperitoneal FU administration potentially could achieve the same end as a portal vein 
infusion. Direct portal vein infusion of FU (assuming a portal vein blood flow of 
0.5 1/min and a CLrB of FU of 5 l/min--see discussion below) should generate a 10-fold 
increased hepatic exposure as compared to the 4-fold increase in portal vein FU level 
anticipated with intraperitoneal administration. 
The contribution of starting the seven day FU infusion immediately post-operatively in 
the prevention of tumor implantation and growth throughout the body versus the 
contribution of higher portal FU levels in killing microscopic intrahepatic implants needs 
to be ascertained. The physiological milieu immediately post-operative may favor im- 
plantation of tumor cells and perhaps even a systemic FU infusion would inhibit such 
implantation if given immediately after operation. It is an accepted principle/phenomenon 
in adjuvant chemotherapy that treatment results are markedly affected by delay in giving 
drug post-operatively. Recently introduced drug delivery devices (external and implantable 
pumps, injection ports) may make randomized trials of portal vein, intraperitoneal, and 
systemic adjuvant treatment with constant infusion FU and other drugs more feasible. 
3. INTRAARTERIAL CHEMOTHERAPY 
Intraarterial chemotherapy has been most extensively applied to the treatment of 
primary and metastatic cancer in the liver. However, other body regions and tumor types 
studied in the past and currently under investigation include external carotid arterial 
infusions for head and neck cancers, internal carotid and vertebral arterial infusions for 
primary and metastatic brain tumors, femoral and brachial arterial infusions for melano- 
mas and sarcomas of the extremities, and infusion of various pelvic arteries for urogenital 
tumors. 
There are a number of often neglected crucial elements in successful intraarterial 
chemotherapy: 1. Use of a drug which has appropriate pharmacokinetics, dose-response 
and schedule dependency; 2. Catheter placement so as to infuse the entire tumor-bearing 
region; 3. Use of a delivery system which allows repeated and chronic administration 
conveniently and reliably, preferably in an outpatient setting. 
3.1. PHARMACOKINETICS 
The theoretical pharmacokinetic basis defining the advantages of intraarterial drug 
infusions has been described by Eckman and associates (Eckman et al., 1974) and by Chen 
and Gross (Chen and Gross, 1980). In order to quantitate the delivery advantage to the 
site in question, the ratio of regional exposure after regional arterial infusion is compared 
to that after venous infusion at the same dose rate. The advantage of increased drug 
delivery resulting from arterial infusion is determined by factors which influence the time 
integrals of the arterial drug levels obtained by arterial vs venous infusion, respectively. 
Using a physiologically based pharmacokinetic model, Chen and Gross (Chen and Gross, 
1980) demonstrated that the regional drug exposure advantage (Rd) for agents with linear 
pharmacokinetics is related to the rate of drug elimination in the rest of the body and the 
blood perfusion rate into the target region by the formula 
Advantage ( R d )  = 1 + CLapp/Qt (8 )  
where CLap p is the total body drug clearance from the rest of the body excluding the tumor 
(target) region and QT is the blood flow through the regional artery being infused. 
Intraarterial infusion will reduce drug delivery and availability to the rest of the body by 
R d = 1 - -  E T (9)  
where Ex is the extraction ratio of the drug by the target region. Combining the advantage 
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TABLE 2. Drugs For Intraarterial Infusion 
Estimated 
Increased Exposure 
T~/2 C ITS With Hepatic 
Drug (min) (1/min) En Arterial Infusion Reference 
FU 10 5 0.80 100 Ensminger et al., 1983 
FUDR < 10 5-15 0.69-0.92 400 Ensminger et al., 1978a 
BCNU <5 2.5 12 Ensminger et al., 1978b 
Mitomycin C < 10 0.6 0.07-0.18 3-4 Gyves et al., 1983 
Cisplatin 20-30 4-7 Kelson et al., 1980 
Dichloromethotrexate 0.40-0.70 6 Ensminger et al., 1981b 
gained through the total body clearance relative to regional blood flow plus that gained 
by regional extraction 
Regional Advantage = 1 4 CLTB _ (0.693 Vd ) /QT( l  _ ET) (10) 
QT(1 - ET) \ t,/---~2 
where CLxB is total body drug clearance, Vd is the volume of distribution, ll/2 the 
elimination half-life and Qx and JET are as noted above. Hence, in analogy with third space 
drug infusions (Eqns 6 and 7), regional selectivity is a direct function of a drug's total body 
clearance. Thus, agents with high total body clearance are essential for maximum effect 
for both third space as well as intraarterial chemotherapy. 
Table 2 presents the pertinent pharmacokinetic parameters and estimates of the 
improved regional hepatic exposure with hepatic arterial drug infusion, the most common 
form of intraarterial infusion practiced. Most of the drugs used in hepatic arterial 
chemotherapy have short plasma half-lives and high total body clearances. The two most 
commonly utilized used drugs, 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR), 
have half-lives of 10min or less with high total body clearances plus extensive hepatic 
extraction. Calculations based on direct blood level determinations indicate as much as a 
100-fold advantage for FU (Ensminger et al., 1983) and a 400-fold advantage for FUDR 
(Ensminger et al., 1978a) of hepatic arterial over intravenous infusion in the generation 
of an improved hepatic drug exposure. Although the data is limited, significantly (i.e. 
> 2-fold) increased exposure with hepatic arterial infusion is seen for a number of other 
agents including dichloromethotrexate (Ensminger et al., 1981b), thymidine (Ensminger 
and Frei, 1978), bischlorethylnitrosourea (Ensminger et al., 1978b), mitomycin C (Tseng 
et al., 1981), and cis-platinum (Kelsen et al., 1980). 
The theoretical principles described above assume that the rate coefficients of drug loss 
remain constant over the complete range of drug concentrations and throughout the time 
periods involved. Data obtained with increasing dose rates of thymidine given into the 
hepatic artery demonstrate that extraction processes can become increasingly saturated 
with the hepatic extraction dropping from 80~o at 4 g/m: per day to less than 20~ at 
128 g/m 2 per day (Ensminger and Frei, 1978). Non-linear pharmacokinetics with saturable 
elimination also apparently hold for infusions of the radiosensitizer 
5-bromo-2'-deoxyuridine (Sonneveld et al., 1982). Recent investigation (Ensminger et al., 
1983) has confirmed the non-linear pharmacokinetics of FU first described by Collins and 
associates (Collins et al., 1980). At dose rates of 20 mg/kg per day as a constant infusion, 
the CLTB of FU is approximately 5 1/min, falling to less than 1 1/min at dose rates exceeding 
270 mg/kg per day. Not only does CLrB fall, but the hepatic extraction ratio falls so that 
at high dose rates given into the hepatic artery, much of the regional specificity may be 
lost (Ensminger et al., 1978a, 1983). 
The administration of a second agent can decrease the total body clearance and make 
a given agent less advantageous regionally. For example, the administration of thymidine 
with FU can decrease the clearance of Fu greatly and virtually eliminate any selectivity 
for hepatic arterial FU (Kirkwood et al., 1980). 
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As the equations above indicate, the concentration of drug in the arterial watershed is 
dependent upon the blood flow rate through the infused artery (assuming high total body 
drug clearance). For example, decreasing the blood flow rate by 90~ should increase the 
arterial concentrations of drug at any given dose rate by about 10-fold. There are at least 
five methods to decrease arterial blood flow. Note that as arterial blood flow is decreased, 
it may become difficult to dissociate therapeutic effects due to resultant ischemia from 
therapeutic effects due to increased drug exposure to the tumor. The five methods for 
decreasing arterial blood flow are best illustrated as applied to hepatic arterial infusion. 
Ligation of the hepatic artery with placement of a catheter in the distal arterial stump 
is one method to simultaneously decrease blood flow to the tumor while exposing the 
tumor to higher drug concentrations (Ramming et al., 1976; Karakousis et  al., 1979). In 
general, the results of this manoeuver are marginally advantageous over intraarterial drug 
infusion alone. Rapid collateralization from a multiplicity of vessels as well as thrombosis 
in the stump around the catheter diverts drug flow to only a small portion of the liver. 
The application of low flow nuclide angiography using injection of a lung scanning agent 
(Tc99m-macroaggregated albumin or TcMAA) through the catheter in such studies can 
document the drug flow distribution as well as thrombus formation (Kaplan et  al., 1978; 
Ensminger et al., 1981a). Ligation has the added drawback of being irreversible. Recently 
a method using operatively positioned strangulation slings on the hepatic artery has been 
examined as a means to produce transient occlusion of the hepatic artery for up to 16 hr 
(Dahl et al., 1981). Intraarterial FU was given concurrently in some of the patients 
undergoing transient hepatic arterial occlusion with this method. The procedure appar- 
ently was well tolerated and permanent arterial thombosis due to the temporary occlusion 
did not occur. 
A second method, usually inadvertant, of decreasing hepatic arterial blood flow, comes 
with clot formation around the indwelling catheter. Clot formation may decrease blood 
flow dramatically prior to total occlusion. This should generate significantly increased drug 
levels in the infused watershed as the formula above would suggest. Such clot formation 
is frequent with the use of percutaneous angiographic catheters (Clouse et al., 1977). One 
recent study noted an improved response rate in those patients where hepatic arterial 
occlusion occurred at some point in their therapy (Patt et al., 1981). This method of 
decreasing the hepatic arterial blood flow is essentially uncontrolled and irreversible. 
Partial occlusion proceeds to total occlusion haphazardly. Once there is total occlusion no 
further hepatic arterial chemotherapy is possible even in patients where a response has 
occurred. With total occlusion, collaterization occurs rapidly so that tumor is still well 
nourished from a multiplicity of alternate arterial sources (Bengrnark and Rosengren, 
1970). Such patients will often die of progressive hepatic tumor once the therapeutic effect 
of thrombosis has been lost. 
A third method for temporary reduction of hepatic arterial blood flow has been the use 
of balloon catheters (Watkins et al., 1960; Cho et al., 1983). Important factors to be 
considered are the degree of obstruction (determined by vessel size and the degree of 
balloon inflation) and the duration of the blood reduction induced by balloon inflation. 
If the reduction of flow can be controlled and quantitated, balloon catheters might prove 
very useful in those regimens where short infusions or bolus injections are given. 
Additional considerations with such regimens are the appropriateness of the drug-schedule 
(see below) and the flow distribution changes brought about by reducing overall hepatic 
arterial blood flow. 
A fourth method for reducing hepatic arterial blood flow has been the infusion of 
vasoconstricting agents such as epinephrine, angiotensin or vasopressin. Such agents have 
been used extensively in pharmacoangiography to better delineate tumor vessels (Abrams, 
1964). The lack of responsive smooth muscle fibers in the wall of tumor vessels provides 
at least the potential for redirecting blood flow from normal liver (responsive arterioles) 
to tumor (non-responsive arterioles) (Hafstrom et al., 1980). Vasoconstricting agents may 
have great impact, additionally, in reducing overall hepatic arterial flow. Direct arterial 
infusion of appropriate concentrations of epinephrine or vasopressin may confine the 
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vasoconstriction to the hepatic arterial watershed. In our experience, as little as 1 #g of 
epinephrine given into the hepatic artery can totally block the hepatic arterial blood flow 
in some patients for as long as 5 min without affecting baseline pulse and blood pressure. 
Contingent upon the pharmacokinetic principle delineated previously, concurrent cyto- 
toxic drug administration while blood flow is reduced should generate higher arterial drug 
levels and thus a greater regional tumor exposure. It should be noted that when 
vasoconstrictors decrease overall flow to the normal liver, systemic drug exposure may 
actually increase for agents with insignificant hepatic extraction (Iwaki et al., 1978). Thus, 
studies involving concurrent vasoconstrictors and cytotoxic agents will need extensive 
monitoring to assure appropriate dose-schedules for maximal tumor exposure without loss 
of regional selectivity due to decreased hepatic extraction. 
A fifth method for decreasing hepatic arterial blood flow is the use of microparticulates 
or microspheres. At sufficiently high doses approximating 90 million biodegradable starch 
microspheres (40 #m diameter), hepatic arterial blood flow can be totally blocked in about 
25~ of patients (Aronsen et al., 1979; Lindell et al., 1978; Dakhil et al., 1982). By 30 min 
after hepatic arterial injection, the starch microspheres are completely lysed by serum 
amylase and flow resumes relatively normally through the hepatic arterial tree as 
ascertained by contrast angiograms. In the remaining 759/0 of patients, hepatic arterial flow 
decreases by 80~o and arterial-venous shunting occurs. As will be described below, the use 
of the hepatic arterial starch microspheres may be an additional method to deliver more 
drug to tumors within the liver. 
3.2. TUMOR VASCULATURE AND BLOOD FLOW 
Based on the radiographic appearances using contrast angiography, it has been 
customary to regard tumors as being either hypo- or hyper-vascular relative to normal 
liver. As tumor nodules grow, the evoked new capillary bed develops at the periphery so 
that the most vascularized area is the outer shell of the nodule (Warren, 1979). Although 
the central core of many tumor nodules in the liver is hypovascular, the periphery of the 
tumor nodule is generally hypervascular relative to normal liver as demonstrated by 
nuclear tomographic scans after hepatic arterial injection of TcMAA (Gyves et al., 
1982b,c). The microvascular pattern is consistent with the distribution of tumor cell 
viability and growth, the central core of the tumor often being necrotic while the peripheral 
rim of actively proliferating tumor cells has an excellent blood supply (Ackerman and 
Hechmer, 1980; Warren, 1979). The presence or absence of a hypovascular core appears 
to relate more to the size of the tumor nodule than to tumor type (Gyves et al., 1982c). 
Nodules below 8 cm in diameter are uniformly hypervascular whereas those over 9 cm in 
diameter display a hypovascular rim as ascertained by radionuclide tomographic angio- 
graphy. The density of vessels in the hypervascular regions of tumor nodules appears to 
be 2-8 fold greater than in normal liver. These observations suggest a number of methods 
whereby tumor hypervascularity can be used for selective therapeutic advantage. 
Tumor vessels tend to lack the smooth muscle layer found in normal precapillary 
arterioles and thus are less sensitive to vasoconstricting agents such as epinephrine or 
vasopressin (Hafstrom et al., 1980; Mattson et al., 1979). If a relative redistribution of 
blood flow occurs with vasoconstricting agents, it may provide a selective advantage in the 
delivery of therapeutic microspheres to hypervascular tumor. Microspheres of 40-80/~ m 
diameter when injected as a homogenous suspension into the hepatic artery should lodge 
in the hepatic arterial microvasculature in direct proportion to regional blood flow 
throughout that watershed. As mentioned earlier, the hepatic arterial injection of TcMAA 
(lung scanning agent) with nuclear tomography provides a means to determine the relative 
blood flow distribution between normal liver and tumor nodules within liver and thus to 
monitor selective delivery of therapeutic microspheres to tumor (Gyves et al., 1982b). 
3.2.1. Therapeutic (Drug and Radiation) Microspheres 
Three varieties of microspheres have been used clinically, two for drug delivery 
(chemoembolization) and one for radiotherapy. Ethylcellulose microspheres which are 
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225 ___ 55 ~tm in diameter and contain 80~ by weight of biologically active mitomycin C 
have undergone recent testing in Japan (Kato et  al., 1980, 1981). Preclinical investigations 
in dogs indicate that drug release occurs over hours and that there is an approximate 60~ 
reduction in circulating systemic mitomycin when mitomycin is encapsulated in micro- 
spheres and administered intraarterially (Kato et al., 1980). In clinical studies, minor 
responses were seen in a small number of patients with regional tumors (Kato et al., 1981). 
Ethylcellulose microspheres are not biogradable and thus should permanently occlude the 
vessel in which they lodge. Hence, the potential therapeutic effects would result from a 
combination of infarction and prolonged, intensified drug exposure. 
As previously mentioned, another approach using biodegradable starch microspheres 
has been developed recently (Aronsen et  al., 1979; Lindell et  al., 1978; Dakhil et  al., 1982). 
The concurrent hepatic arterial injection of a suspension of starch microspheres in a drug 
solution has the potential of temporarily holding the drug solution in the hepatic arterial 
capillary bed thus allowing more time for the higher drug concentration to move into 
surrounding tissue. Bischlorethylnitrosourea (BCNU) and mitomycin C have been exam- 
ined in conjunction with starch microspheres given via the hepatic artery (Dakhil et al., 
1982; Gyves et  al., 1982d). These agents were chosen due to their rapid tissue uptake and 
mechanism of action as alkylating agents (i.e., peak drug levels are important). Due to 
increased drug delivery to the liver and hepatic tumor, systemic drug exposure was reduced 
up to 90~ for BCNU and 50~ for mitomycin C when drug was given with starch 
microspheres versus drug injection alone. In hypervascular regions of tumors, more drug 
solution should be held up as compared to the drug entrapment in less vascular regions 
of normal liver. As the microspheres are digested, their diameter progressively decreases 
(from 40/~m initially) and the drug column moves distally into the capillary bed. Due to 
complete dissolution of the starch microspheres by 30 min post-injection, subsequent doses 
can be administered without destroying access to the tumor microcirculation. Repeated 
dosage studies and clinical trials comparing hepatic arterial BCNU and mitomycin with 
and without starch microspheres are in progress. 
Yttrium-90 resin microspheres with a 55 #m diameter have been used both in model 
systems (Blanchard et  al., 1965) and in the clinic to treat hepatic tumors with internal 
radiotherapy (Abel, 1965; Grady, 1979). In the Walker carcinosarcoma rat liver tumor, 
yttrium-90 microspheres lodge in highest concentrations in the hypervascular tumor 
periphery (Ackerman and Heckmer, 1980). Concurrent epinephrine administration de- 
creases yttrium-90 microsphere concentration in normal liver and markedly increases 
concentrations in the tumor in this rat model. In several patients, metastatic tumors were 
found to have 3-4-fold higher yttrium-90 microsphere levels than normal liver (Grady, 
1979; Grady et  al., 1980). Yttrium-90 microspheres have a short effective kill distance of 
2-3 mm and deliver the majority of their dose over about 3 days. Tomographic nuclear 
angiography (see above) with TcMAA may be essential to the safe use of yttrium as well 
as starch microspheres in that the therapeutic microspheres must go to the tumor for 
efficacy and not to the stomach, duodenum, or lungs if severe toxicity is to be prevented. 
5-Bromo-2'deoxyuridine (BUDR) is an analogue of thymidine which is incorporated 
solely and specifically into the DNA of replicating cells. BUDR undergoes debromination 
in the liver, and in analogy with fluorodeoxyuridine and thymidine (Ensminger et  al., 
1978a; Ensminger and Frei, 1978), can be expected to have high hepatic extraction. BUDR 
has pharmacokinetic properties including a high total body clearance (5-151/min) making 
it suitable to hepatic arterial infusion for selective regional effects (Schwade et  al., 1981). 
BUDR by hepatic arterial infusion should be incorporated selectively into proliferating 
tumor within the liver since there is usually little hepatic parenchymal DNA synthesis. For 
maximum incorporation of BUDR into DNA, prolonged exposure is necessary 
(Djordjevec and Szbalski, 1960; Sano et al., 1968; Schindler et al., 1966). Such prolonged 
exposure should be possible using the totally implanted system for hepatic arterial infusion 
described below. With sufficient incorporation into both strands of DNA, radiation 
sensitivity can be increased at least 2-fold. Studies with BUDR and yttrium-90 micro- 
spheres have not been done, but the combination would be expected to have considerable 
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selective antitumor potential. Preclinical studies with this combination are in progress. The 
implanted system should allow continuous infusion of BUDR via the central pumping 
mechanism whereas the pump sideport can be utilized for yttrium-90 microsphere 
injection. Further selectivity using both starch and yttrium microspheres may be possible 
through the concurrent administration of vasoconstrictors to shift flow from normal liver 
into the tumor microcirculation. 
3.3. DOSE RESPONSE 
The second element in the evaluation of the appropriateness of a drug for hepatic arterial 
chemotherapy is the dose-response curve for that drug in the tumor type in question. By 
arterial infusion one attempts to expose the tumor to more drug than is otherwise possible. 
However, if the tumor is extremely sensitive to a given drug, then the exposure with 
intravenous chemotherapy may be sufficient to kill the entire sensitive cell population. If, 
on the other hand, the tumor is absolutely resistant to the drug, then even increasing the 
exposure by a hundred-fold, as is possible with hepatic arterial infusion of some drugs 
(Table 2), may not produce noticeable antitumor response. If an agent is reported to have 
marginal activity when given intravenously in a particular tumor, then exploiting the 
dose-response curve through hepatic arterial infusion may be profitable (Frei and 
Canellos, 1980). For example, FU and FUDR both have definite, but marginal activity, 
in colorectal cancer. Hence, generating a marked increase in exposure by hepatic arterial 
infusion of FU or FUDR is more likely to be of benefit than the use of another agent, 
such as cytosine arabinoside, which has essentially no activity in this disease (although the 
use of cytosine arabinoside would be appropriate pharmacokinetically). 
When the dose-response for an agent is sufficiently steep and the pharmacokinetics 
appropriate, it should be possible to generate cytotoxic drug levels in the hepatic arterial 
tree with lower, non-toxic systemic levels. In fact, this should be reflected in the toxicity 
observed, i.e. dose-limiting toxicity should be regional (liver), and not systemic (bone 
marrow or gut). It should be noted that the doses and schedules of agents can be so selected 
as to achieve maximum tolerated systemic levels with supramaximal effects on the tumor 
in the liver. For example, this is possible with FU due to its 50-80~o hepatic extraction 
(Ensminger et  al., 1978a, 1983). Three times the systemic dose can be given by the hepatic 
artery to achieve at least a 50-fold increased exposure to the liver tumor, yet the same 
systemic exposure (to extrahepatic tumor) occurs as is produced by intravenous infusion. 
3.4. SCHEDULE DEPENDENCY 
A third consideration is the drug's schedule dependency which is best defined in 
preclinical animal and cell culture experiments (Blum et al., 1982). Schedule dependency 
is based on the biochemical and cytokinetic actions of the agents in question. For example, 
in the case of alkylating agents, bolus injections for short term peak exposure may produce 
maximal damage to the nucleic acids of cells. Lower drug levels with constant infusions 
can allow rate-limited repair processes to occur more efficiently and thereby prevent 
lethality (Skipper and Schabel, 1982). Alternatively, antimetabolites generally produce 
cytotoxicity as a function of duration of exposure above a given concentration (Chabner 
and Young, 1973). The drug schedule dictates the type of delivery system necessary. 
Prolonged controlled infusions will require a pumping system. Short infusions or boluses 
may be given by hand injection or by a temporary pump attachment. 
3.5. ADEQUACY OF INTRAARTERIAL INFUSION 
There are several difficulties unique to intraarterial chemotherapy which are not found 
with systemic, intravenous drug administration. Although a drug may be pharma- 
cologically rational, it must be delivered directly into the tumor blood supply in a reliable 
and reproducible manner. For example, with protracted (i.e., greater than 3 weeks) hepatic 
arterial infusion using percutaneous angiographic catheters or surgically placed plastic 
catheters, progressive hepatic arterial thrombosis occurs at a high rate and gradually 
produces decreased blood flow and ultimately occlusion (Cady, 1973; Clouse et al., 1977). 
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Any improvement in response (Patt et  al., 1981) (brought about through resultant ischemia 
and higher drug levels generated) must be tempered by the inability to use further arterial 
chemotherapy. It also has been shown that the pattern of distribution of agents injected 
intraarterially is dependent upon the flow rate of the infusion (Kaplan et  al., 1978). 
Radionuclide angiography using Tc99m-macroaggregated albumin (TcMAA) appears to 
give the best representation of drug distribution at the low infusion rates (3-1000 ml per 
day) clinically used (Kaplan et  al., 1980). When percutaneous angiographic catheters are 
used, the tip of the catheter tends to move about and leads to frequent and unpredictable 
flow distribution changes. In hepatic arterial infusions, when drug is infused inadvertently 
into a gastric artery, severe gastric damage can result (Chuang et al., 1981; Narsete et al., 
1977). Hence, a catheter system free of thrombosis and movement which reliably infuses 
only the tumor containing region or organ is a prerequisite for maximum response with 
minimal toxicity. The more potent the cytotoxic agent for intraarterial use, the more 
important the focusing of the flow from the catheter. Surgical placement of soft silastic 
catheters in a manner to minimize turbulence in blood flow represents the most durable 
intraarterial access at present. Nuclide angiography to guide in catheter placement and to 
ascertain complete drug flow distribution is equally important (Yang et al., 1982). 
3.6. DRUG DELIVERY SYSTEMS FOR INTRAARTERIAL USE 
Intraarterial drug infusions have been limited by the type of pumping system involved. 
Pumps worn externally by patients have proven inconvenient because of their bulkiness 
and have been a major hindrance to normal daily activities. The pump and the external 
catheter connection have represented sites for the interruption of the infusion path leading 
to bleeding, catheter thrombosis, or infection from the introduction of pathogenic 
organisms. The fact that patients have undergone protracted outpatient treatment using 
external pumps is witness more to the fortitude of the patient than to the ingenuity of their 
physicians and the biomedical engineers. The need for multiple supportive personnel to 
maintain prolonged outpatient infusions and the clumsiness and unreliability of the 
infusion systems has limited their widespread applicability. 
A totally implanted drug delivery system tested over the past several years appears to 
overcome many of the problems noted above and has been applied to intraarterial 
infusional therapy of head and neck cancer (Baker et al., 1981), brain tumors (Phillips et 
al., 1982), and liver cancer (Ensminger et  al., 1981a; Buchwald et  al., 1980). The most 
extensive experience has been with hepatic arterial chemotherapy where, at laparotomy, 
a small flexible silastic catheter is implanted so as to infuse the entire liver. Appropriate 
vessels are ligated in an effort to confine drug flow to the liver (Niederhuber and 
Ensminger, 1983). The catheter is attached to a subcutaneously placed Model 400 Infusaid 
pump (Fig. 1). In the first 60 patients with colorectal cancer metastatic to liver treated with 
this system at the University of Michigan, there was only one hepatic artery occlusion 
(immediately post-operatively) and one permanent catheter occlusion (Ensminger et al., 
1982). Flow distribution to the entire liver ascertained by radionuclide angiography was 
maintained in the other 58 patients. Autopsies in six patients having catheters in place for 
up to 18 months showed no evidence of thrombosis or vessel wall damage in the 
catheterized artery. These patients as a group received 13,000 cumulative days of hepatic 
arterial infusion and 900 pump refills without a bleeding or infectious episode. Over 95~o 
of the days of infusion were given as outpatients. Patients were able to function relatively 
normally since the system was totally implanted under the skin. This system has been 
found to function reliably for other investigators as well (Barone et  al., 1982). The model 
400 Infusaid pump has a sideport allowing direct injection into the hepatic artery catheter. 
The 0.63 mm lumen on the hepatic arterial catheter readily allows the passage of TcMAA, 
starch microspheres and other forms of microspheres. The recent approval by the Food 
and Drug Administration of the Infusaid pump for hepatic arterial infusion with FUDR 
has facilitated dissemination of the device. 
Preliminary therapeutic results in the treatment of hepatic cancers have been excellent 
with the implanted system (Ensminger et  al., 1982). The Model 400 Infusaid pump holds 
290 W.D.  ENSMINGER and J. W. GYVES 
50 ml of solution with a typical flow rate of 2-3 ml/day and, for hepatic arterial 
chemotherapy, pumps are refilled every two weeks, alternating two weeks of FUDR 
(0.3 mg/kg per day) with two weeks of saline in order to decrease the propensity for 
chemical hepatitis. Hepatic tumor response ascertained by physical examination and liver 
scan using standard criteria was seen in 50/60 (83~o of patients). Only one patient had 
progessive growth of liver metastases. Response durations to initial FUDR therapy ranged 
from 2 to 24 + months. Hepatic arterial mitomycin through the pump sideport was added 
to FUDR when response was no longer evident or when extrahepatic disease became 
manifest. Ninety-eight percent (47/48) of patients with an elevated carcinoembryonic 
antigen level had at least a 50~ fall in levels with treatment. Median survival by life table 
analysis for patients with diseases confined to the liver at operation has been 24 months. 
For patients with disease outside of the liver, median survival has been 8-10 months. 
Toxicities were all reversible and consisted of mild gastritis in 56~ of patients, ulcers in 
8~o, and, anicteric (23~ of patients) and icteric (23~ of patients) hepatitis. With 
dose-schedule modifications, all patients showing toxic effects were able to continue 
treatment without recurrence of toxicity. 
In situations where repeated arterial access is required for boluses or short infusions, 
it may not be necessary to implant the infusion pump. Implantable injection ports attached 
to silastic catheters can be used (Gyves et al., 1982a). Such ports are much less expensive, 
less noticeable, and generally do not require frequent flushing between uses. 
4. SUMMARY 
Recent developments have made regional chemotherapy a more rational endeavour. The 
important pharmacokinetic principles have been defined. The increase in regional exposure 
achieved is a direct function of a drug's total body clearance and is an inverse function 
of the permeability-area product (defining ease of egress) for third spaces or of the regional 
arterial blood flow for intraarterial infusion. Agents having appropriate properties are 
available. For new agents with appropriate pharmacokinetic parameters, regional chemo- 
therapy may provide a means to examine the dose response against measurable tumors 
in the regions in question. 
The observation that most tumors are hypervascular may be crucial to the development. 
of selective treatments using microspheres to deliver therapy in direct proportion to th~ 
density of the microvasculature. Regionally infused vasoconstrictors (epinephrine, angio- 
tensin) may allow shunting of flow away from normal tissue toward tumor without 
potentially serious systemic cardiovascular effects. Investigations and applications of 
regional chemotherapy have been fostered immensely by the reliably and convenience of 
the Infusaid implantable pump and by implantable injection ports. The problem of 
systemic failure with regional approaches still remains but is approachable using pharma- 
cologically rational programs aimed at delivering maximal systemic chemotherapy along 
with regional treatment. In hepatic arterial therapy, in particular, a randomized prospec- 
tive study is being considered to examine the impact of such combined treatment versus 
regional therapy alone and versus systemic chemotherapy alone for metastatic colorectal 
cancer to liver. Thus, the future for regional chemotherapy appears exciting. There are 
many opportunities to apply therapeutic principles rationally with the potential of 
significant benefit to many patients. 
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